A new model of
addiction care with psychedelic therapeutics

imagined brain slices in 2 parts
scroll down

Journey's mission is to unlock the promising science behind psychedelics to provide durable remission to patients suffering from addiction

Backed by world class investors

We believe a powerful new model of addiction treatment can be created by combining the promise of psychedelic therapies with an integrated care model that includes psychotherapy and community support.

Our approach:

  • Enable real-world research on psychedelic therapeutics and high-quality, integrated care through our network of Centers of Excellence, created in collaboration with select addiction treatment centers across the U.S.
  • Advance psychedelic therapeutic development, including Journey’s own drug program, JOUR-5700, Mescaline HCl for Alcohol Use Disorder

Addressing addiction

Journey Colab is focused on finding new and better solutions for those who are in desperate need of durable remission from this chronic, relapsing condition.

Why psychedelics for addiction?
2021 vs 2027 Addiction Levels:
Cost of addiction in 2021 - $15B;
Cost of addiction in 2027 - $30B


Americans suffer from addiction today. Only 10% receive lasting benefit from current treatments. ~75% of substance use cases are alcohol-related.


in estimated annual expenditure in U.S. on SUD (2020)


of adults with SUD don’t get treatment


in the estimated economic burden in the U.S. from SUD (2022)

Built with reciprocity in mind

Through our unique stakeholder structure, we have built an experienced team dedicated to our mission of creating scientifically rigorous and clinically validated treatments and improving equitable access to care. Ten percent of our founding equity is dedicated to sharing success with community stakeholders, including Indigenous communities, to increase equitable access to care and recruit employees and partnerships.

Our reciprocity

Interested in getting involved?

Contact Us

Latest news

Journey Colab is an intentionally non-traditional pharmaceutical startup that believes pharmacotherapy should be part of an integrated solution to treat addictions and other mental health conditions.

See more
scroll down
Journey featured in Newsweek's Medical Marvels Disrupting Healthcare
Learn more
Privacy Policy Cookie Policy Terms and Conditions